Calcium channel antagonists: Morbidity and mortality - What's the evidence?

American Family Physician

Volumn 57, Issue 7, 1998, Pages 1551-1560

  Straka, Robert J ^a,c   Swanson, Amy L ^a   Parra, David ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c REGIONS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; BEPRIDIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; FELODIPINE; HEPARIN; ISRADIPINE; LISINOPRIL; MIBEFRADIL; NICARDIPINE; NIFEDIPINE; NIMODIPINE; NISOLDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID; VERAPAMIL;

ADULT; AGED; ANGINA PECTORIS; ANTIHYPERTENSIVE THERAPY; CANCER RISK; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG SAFETY; EMERGENCY TREATMENT; GASTROINTESTINAL HEMORRHAGE; GERIATRIC PATIENT; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; META ANALYSIS; MORBIDITY; MORTALITY; ORAL DRUG ADMINISTRATION; PRACTICE GUIDELINE; REVIEW; SUBLINGUAL DRUG ADMINISTRATION; TREATMENT INDICATION;

ADMINISTRATION, SUBLINGUAL; AGED; CALCIUM CHANNEL BLOCKERS; GASTROINTESTINAL HEMORRHAGE; HUMANS; HYPERTENSION; INCIDENCE; MYOCARDIAL INFARCTION; NEOPLASMS; NIFEDIPINE; RISK ASSESSMENT; SURVIVAL RATE;

EID: 0032054024     PISSN: 0002838X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Manolio TA, Cutler JA, Furberg CD, Psaty BM, Whelton PK, Applegate WB. Trends in pharmacologic management of hypertension in the United States. Arch Intern Med 1995;155:829-37.
2. JNC VI. The sixth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157:2413-45.
3. Drug Facts and Comparisons. St. Louis, Mo.: Lippincott, 1998:149.
4. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620-5.
5. Furberg CD, Psaty BM, Meyer JV. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995;92: 1326-31.
6. National Heart, Lung, and Blood Institute. New analyses regarding the safety of calcium-channel blockers: a statement for health professionals from the National Heart, Lung, and Blood Institute. Statement issued Sept. 1, 1995.
7. Pahor M, Guralnik JM, Furberg CD, Carbonin P, Havlik R. Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet 1996;347:1061-5.
8. Pahor M, Guralnik JM, Ferrucci L, Corti MC, Salive ME, Cerhan JR, et al. Calcium-channel blockade and incidence of cancer in aged populations. Lancet 1996;348:493-7.
9. Epstein M. Calcium antagonists should continue to be used for first-line treatment of hypertension. Arch Intern Med 1995;155:2150-6.
10. Kloner RA. Nifedipine in ischemic heart disease. Circulation 1995;92:1074-8.
11. Wagenknecht LE, Furberg CD, Hammon JW, Legault C, Troost BT. Surgical bleeding: unexpected effect of a calcium antagonist. BMJ 1995;310:776-7.
12. Egstrup K, Andersen PE Jr. Transient myocardial ischemia during nifedipine therapy in stable angina pectoris, and its relation to coronary collateral flow and comparison with metoprolol. Am J Cardiol 1993;71:177-83.
13. Ruzicka M, Leenen F. Relevance of intermittent increases in sympathetic activity for adverse outcome on short-acting calcium antagonists. In: Laragh J, Brenner B, eds. Hypertension: pathophysiology, diagnosis, and management. New York: Raven, 1995:2815-25.
14. Stone PH, Muller JE, Turi ZG, Geltman E, Jaffe AS, Braunwald E. Efficacy of nifedipine therapy in patients with refractory angina pectoris: significance of the presence of coronary vasospasm. Am Heart J 1983;106:644-52.
15. Thadani U, Zellner SR, Glasser S, Bittar N, Montoro R, Miller AB, et al. Double-blind, dose-response, placebo-controlled multicenter study of nisoldipine. A new second-generation calcium channel blocker in angina pectoris. Circulation 1991;84: 2398-408.
16. Packer M. Pathophysiological mechanisms underlying the adverse effects of calcium channel-blocking drugs in patients with chronic heart failure. Circulation 1989;80:IV59-67.
17. Roine RO, Kaste M, Kinnunen A, Nikki P, Sarna S, Kajaste S. Nimodipine after resuscitation from out-of-hospital ventricular fibrillation. A placebo-controlled, double-blind, randomized trial. JAMA 1990;264:3171-7.
18. Brain Resuscitation Clinical Trial II Study Group. A randomized clinical study of a calcium-entry blocker (lidoflazine) in the treatment of comatose survivors of cardiac arrest. N Engl J Med 1991; 324:1225-31.
19. Gore JM, Sloan M, Price TR, Randall AM, Bovill E, Collen D, et al. Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the Thrombolysis in Myocardial Infarction Study. Thrombolysis in Myocardial Infarction, Phase II, pilot and clinical trial. Circulation 1991;83:448-59.
20. Lubbe WF, Podzuweit T, Opie LH. Potential arrhythmogenic role of cyclic adenosíne monophosphate (AMP) and cytosolic calcium overload: implications for prophylactic effects of beta-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors. J Am Coll Cardiol 1992; 19:1622-33.
21. Bigger JT Jr, Coromilas J, Rolnitzky LM, Fleiss JL, Kleiger RE. Effect of diltiazem on cardiac rate and rhythm after myocardial infarction. Multicenter Diltiazem Postinfarction Trial Investigators. Am J Cardiol 1990;65:539-46.
22. Waters D. Proischemic complications of dihydropyridine calcium channel blockers. Circulation 1991;84:2598-600.
23. Carboni GP, D'Ermo M, Mattioli M, Lioy E, Biffani G. The response of the coronary collateral circulation to acute administration of nifedipine: an angiographic and ergometric study. Int J Cardiol 1986;11:25-36.
24. Malacoff RF, Lorell BH, Mudge GH Jr, Holman BL, Idoine J, Bifolck L, et al. Beneficial effects of nifedipine on regional myocardial blood flow in patients with coronary artery disease. Circulation 1982;65:132-7.
25. Kugiyama K, Yasue H, Horio Y, Morikami Y, Fujii H, Koga Y, et al. Effects of propranolol and nifedipine on exercise-induced attack in patients with variant angina: assessment by exercise thallium-201 myocardial scintigraphy with quantitative rotational tomography. Circulation 1986;74:374-80.
26. Bonaduce D, Muto P, Morgano G, Canonico V, Breglio R, Salvatore M, et al. Effect of nifedipine on dipyridamole thallium-201 myocardial scintigraphy. Clin Cardiol 1986;9:285-8.
27. Hayward R, Hunter GJ, Swanton H. Effects of nifedipine on coronary perfusion; recent assessment by parametric digital subtraction. Eur Heart J 1987;8:1-7.
28. Furberg CD, Pahor M, Psaty BM. The unnecessary controversy. Eur Heart J 1996;17:1142-7.
29. Pahor M, Guralnik JM, Salive ME, Corti MC, Carbonin P, Havlik RJ. Do calcium channel blockers increase the risk of cancer? Am J Hypertens 1996; 9:695-9.
30. Connor J, Sawczuk IS, Benson MC, Tomashefsky P, O'Toole KM, Olsson CA, et al. Calcium channel antagonists delay regression of androgen-dependent tissues and suppress gene activity associated with cell death. Prostate 1988;13:119-30.
31. Juntti-Berggren L, Larsson O, Rorsman P, Ammala C, Bokvist K, Wahlander K, et al. Increased activity of L-type Ca2+ channels exposed to serum from patients with type I diabetes. Science 1993;261: 86-90.
32. Ray SD, Kamendulis LM, Gurule MW, Yorkin RD, Corcoran GB. Ca2+ antagonists inhibit DNA fragmentation and toxic cell death induced by acetaminophen. FASEB J 1993;7:453-63.
33. Zacharski LR, Moritz TE, Haakenson CM, O'Donnell JF, Ballard HS, Johnson GJ, et al. Chronic calcium antagonist use in carcinoma of the lung and colon: a retrospective cohort observational study. Cancer Invest 1990;8:451-8.
34. Pales J, Palacios-Araus L, Lopez A, Gual A. Effects of dihydropyridines and inorganic calcium blockers on aggregation and on intracellular free calcium in platelets. Biochim Biophys Acta 1991;1064:169-74.
35. Blache D, Ojeda C. Comparative inhibitory effects of dihydropyridines on platelet aggregation, calcium uptake and cyclic AMP concentration. Pharmacology 1992;45:250-9.
36. Berkels R, Klaus W, Boller M, Rosen R. The calcium modulator nifedipine exerts its antiaggregatory property via a nitric oxide mediated process. Thromb Haemost 1994;72:309-12.
37. National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Circulation 1994;89:1333-445.
38. Pahor M, Guralnik JM, Corti MC, Foley DJ, Carbonin P, Havlik RJ. Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995;43:1191-7.
39. van Harten J, Burggraaf K, Danhof M, van Brummelen P, Breimer DD. Negligible sublingual absorption of nifedipine. Lancet 1987;2:1363-5.
40. Grossman E, Messerli FH, Grodzicki T, Kowey P. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA 1996; 276:1328-31.
41. McAllister RG Jr. Kinetics and dynamics of nifedipine after oral and sublingual doses. Am J Med 1986;81:2-5.
42. Messerli FH, Kowey P, Grodzicki T. Sublingual nifedipine for hypertensive emergencies. Lancet 1991;338:881.
43. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II - DAVIT II). Am J Cardiol 1990;66:779-85.
44. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385-92.
45. Rehnqvist N, Hjemdahl P, Billing E, Bjorkander I, Eriksson SV, Forslund L, et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris. Eur Heart J 1996;17(1):76-81.
46. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107-14.
47. Cohn JN, Ziesche S, Smith R, Anand I, Dunkman WB, Loeb H, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HeFT III. Vasodilator-Heart Failure Trial (V-HeFT) Study Group. Circulation 1997;96(3):856-63.
48. Saunders E. Recruitment of African-American patients for clinical trials - the Allhat challenges. Antihypertensive and Lipid-lowering Trial to Prevent Heart Attack. J Natl Med Assoc 1995;87: 627-9.